IgGenix
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
681 Gateway Blvd Fl 4, South San Francis...Phone Number
(650) 491-9626Website
www.iggenix.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About IgGenix
IgGenix is a clinical-stage antibody discovery and development company focused on addressing allergies and other immunological diseases. Utilizing their SEQ SIFTER antibody discovery platform, they develop innovative products aimed at providing effective clinical responses for both pediatric and adult patients. Their lead candidate, IGNX001, is a first-in-class antibody designed to block the allergic cascade, specifically targeting food allergies. The company conducts research and clinical trials to advance their pipeline, which includes therapies for various food and environmental allergies.Explore more
IgGenix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is IgGenix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once IgGenix has new funding data
Earning: See what the market has to say on IgGenix recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at IgGenix
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if IgGenix has recently received funding, and reach out quickly before it becomes old news!
Click to see if IgGenix had a recent Job posting/layoffs
Check out if IgGenix is spiking on competitors!
Product Launch: Get notified when IgGenix launches new products
IgGenix, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at IgGenix
Find 2 more new buyers
Compare Similar Companies to IgGenix
Compare insights from companies similar to IgGenix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
IgGenix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
IgGenix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about IgGenix.
IgGenix financials insights
Gather financial insights about IgGenix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$25M
2023
Series B
$40M
IgGenix Tech Stack
A closer look at the technologies used by IgGenix
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
IgGenix News & Media
IgGenix Presents Data Supporting Clinical Development of IGNX001 for Peanut Allergy at the 2024 ASCIA Annual Conference
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2024 /PRNewswire/ -- IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to address IgE-mediated diseases, presented exciting data on the company's lead candidate, IGNX001, an IgG4 monoclonal...IgGenix Demonstrates Potential of IGNX001 as a Targeted Therapeutic for Peanut Allergy at the 2024 EAACI Annual Meeting Ahead of Clinical Trial Launch
Additional data presented showcased the expansive potential of the SEQ SIFTER™ platform in the discovery and characterization of IgE antibodies in Atopic Dermatitis SOUTH SAN FRANCISCO, Calif., June 3, 2024 /PRNewswire/ -- IgGenix, Inc., a preclinical antibody discovery and development...IgGenix Presents Groundbreaking Research Using its SEQ SIFTER™ Antibody Discovery Platform for Lead Program in Peanut Allergy at the 2024 AAAAI Annual Meeting
Research Outcomes Include a Novel IgG4 Monoclonal Antibody-based Therapeutic Approach for Addressing Peanut Allergy SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 /PRNewswire/ -- IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to address...IgGenix Demonstrates Potential for an IgG4 Monoclonal Antibody-based Approach to Treating Peanut Allergy
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to directly address allergic disease, today announced advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies. These data will be presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, taking place in Hamburg, Germany on June 9-11, 2023. Highlights from the EAACI Data Nearly all pe
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding IgGenix
Sign Up For FreeTo access detailed company insights
IgGenix is a clinical-stage antibody discovery and development company focused on addressing allergies and other immunological diseases. Utilizing their SEQ SIFTER antibody discovery platform, they develop innovative products aimed at providing effective clinical responses for both pediatric and adult patients. Their lead candidate, IGNX001, is a f... Read More
